Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NextCell Pharma’s updated growth strategy

NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company has decided to implement strategic changes. The new strategic direction means, amongst other things, that Cellaviva will become a wholly owned subsidiary and that the company's GMP facility will have new sources of revenue. The strategic changes will also result in cost savings as a result of staff reduction.NextCell develops the cell therapy drug ProTrans for the treatment of type 1 diabetes. ProTrans is now being evaluated in NextCell's largest study to date, ProTrans Young (the paediatric study), a clinical

edyoutec’s German subsidiaries have signed orders with a total worth of approx 7.35 MSEK (644.000 EUR) during the first two months of 2024

Press release February 27, 2024 edyoutec’s German subsidiaries have had a successful start to 2024 by signing a number of new projects worth approx 7.35 MSEK (644.000 EUR) during January and February.Besides the already reported orders by the city of Bielefeld and graphical work for an existing client worth 3.4 MSEK (290.000 EUR), edyoutec subsidiaries Unger & Fiedler and Wegesrand report the signing of a total of 3.95 MSEK (354.000 EUR) in new orders values. Unger & Fiedler have signed further deals to carry out graphical work for triple A videogames worth a total of approximately 2.

Safello launches podcast about the crypto market

Stockholm 27 February 2024 | Safello, the leading cryptocurrency exchange in the Nordics, launches ”Kryptopodden”, a news podcast based on current events about cryptocurrencies, decentralized finance, and the financial markets. The podcast will offer listeners both knowledge and insights by regularly inviting well-known figures from both the crypto and financial industries as guests to analyze and discuss the latest events from the crypto world. The goal is to feature a variety of voices in the podcast to provide listeners with a broad range of coverage. ”Our ambition is for

LEAX Interim Financial Report Q4 2023

Results improving, executing our long-term strategy remains top priorityThe fourth quarter in summary •                           Net Sales increased to SEK 577.3 million (501.0) •                           Operating profit increased to SEK 3.8 million (-10.9) •                           Earnings before tax (EBT) increased to SEK -13.8 million (-17.9) •                           Net income for the period increased to SEK -16.9 million (-67.2) •                           Cash flow from operating activities amounted to SEK 60.1 million (30.5) The full year in summary •

Year-End Report – January – December, 2023 Redsense Medical AB (publ)

October – December 2023 · Net sales amounted to kSEK 8,025 (8,027). · Operating loss, EBIT amounted to kSEK -927 (555). · Result after tax amounted to kSEK -950 (-2,297). · Earnings per share were SEK -0.07 (-0.16). Significant events during the period · On October 26, Redsense Nomination Committee for the 2024 Annual General Meeting was announced. · On December 23, Redsense notified the market that Chairman of the Board, Patrik Byhmer, passed away. Significant events after the period · On January 8, Redsense announced that Eva Walde was appointed new

AcuCort receives its first order of Zeqmelit®

AcuCort has received its first order of the oral film Zeqmelit®. The order value will have a significant positive impact on the company's financial results.– This order signifies a crucial milestone in AcuCort's history, says Jonas Jönmark, CEO of AcuCort.Zeqmelit®, a rapidly dissolving oral film administered on the tongue for the treatment of severe to acute allergies, is in an intensive commercialization phase. Now, the first order has been received. The purchaser is Unimedic Pharma, also responsible for Zeqmelit® sales in the Nordic region. The order includes Zeqmelit® in its three

Cereno Scientific releases Insights Videos Season 3 Episode 6 with Dr. Raymond Benza, System Director of Pulmonary Hypertension, Mount Sinai Health System

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that episode 6 of Season 3 in the Insights Video Series has been released. In the video, recorded at the Pulmonary Vascular Research Institute (PVRI) Annual Congress 2024, Dr. Raymond Benza, System Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City, Principal Investigator of the Phase II study of CS1, and member of Cereno’s Scientific Advisory Board, talks about the future of treating pulmonary arterial

Aker Carbon Capture awarded milestone project in the United States.

CO280 Solutions and a leading pulp and paper company have awarded a carbon capture test campaign to Aker Carbon Capture for an undisclosed site on the Gulf Coast in the US. This test campaign follows a successful pre-FEED performed for the same site. It will enable the full-scale implementation of multiple Just Catch 400 modular capture facilities with permanent storage, and the creation of carbon removal credits.Aker Carbon Capture has extensive testing experience, with more than 60,000 operational hours worldwide on multiple industrial flue gases. The company’s mobile test unit will now

Annual General Meeting in Heimstaden AB (publ)

The English text is an unofficial translation of the Swedish original. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.The shareholders of Heimstaden AB (publ), reg.no. 556670-0455 (the “Company”), are hereby summoned to the annual general meeting on Thursday 4 April 2024, at 10:00 a.m. CEST at the Company’s premises on Carl Gustafs Väg 1, Malmö. Registration for the general meeting will commence at 09:30 a.m. CEST. Notice of attendance etc. Shareholders who wish to attend and vote at the general meeting must: both

Repurchases of shares by Concentric AB during week 8, 2024

Between 19 February 2024 and 23 February 2024 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 24,566 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission

Heimstaden: 2023 Annual, Governance, and Sustainability Report, SEK Hybrid Bond Interest Payments Deferral, and No-Dividend proposal on any share classes.

Heimstaden AB publishes the 2023 Annual, Governance, and Sustainability Report and has decided to defer interest payments on SEK hybrid bonds and proposes to the AGM that no dividend on any share classes is paid.Highlights (figures in brackets: previous quarter): · The residential operating environment remains strong. Like-for-like rental growth increased to 5.6% (4.2%) and real economic occupancy increased to 98.4% (98.1%) · The NOI margin grew to 66.0% when compared to 61.8% a year ago and the FY NOI margin was 67.4% (66.4%) · Investment properties was valued at SEK 321 billion

Heimstaden Bostad: 2023 Annual, Governance, and Sustainability Report

Highlights (figures in brackets: previous quarter): · The residential operating environment remains strong. Like-for-like rental growth increased to 5.6% (4.2%) and real economic occupancy increased to 98.4% (98.1%) · The NOI margin grew to 66.0% when compared to 60.8% a year ago and the FY NOI margin was 67.4% (66.2%) · Investment properties was valued at SEK 319 billion (332) and comprised 161,553 homes (161,532) · Fair value change before currency effects was -1.6% (-1.5%) primarily driven by continued yield expansion in Sweden and Germany, while valuations were stabilising

Orthex’s Financial statements release 2023 and invitation to the result presentation on 5 March 2024

Orthex Corporation, Press release, 27 February 2024 at 9.00 a.m. EETOrthex will publish its Financial statements release for the period January−December 2023 on Tuesday, 5 March 2024 at around 9.00 a.m. EET. Following the publication, the release will be available in pdf-format on the corporate website at https://investors.orthexgroup.com/.Orthex’s CEO Alexander Rosenlew, CFO Saara Mäkelä and CMSO Hanna Kukkonen will present the full-year report on the same day at 11.00 a.m. EET in a webcast. The webcast can be joined through this link . The result

Repurchases of shares in Attendo during week 8, 2024

On 23 February 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 132,981 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 110,000,000 that Attendo announced on 8 February 2024. The repurchase program, which runs between 9 February 2024 and 24 April 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052.

Immedica’s partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

Stockholm, February 27, 2024 – Immedica’s partner Actinium Pharmaceuticals, Inc. presented four abstracts at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT® (American Society for Transplantation and Cellular Therapy and CIBMTR® (Center for International Blood and Marrow Transplant Research) on February 21 – 24, 2024 in San Antonio, Texas. Two oral presentations and two poster presentations highlighted results from the positive Phase 3 SIERRA trial of Iomab-B ([131]I-Apamistamab). Altogether 10 oral presentations of the SIERRA results have been

EQT X hits the hard cap, raising EUR 22 billion (USD 24 billion) in total commitments

· In what is EQT’s largest ever fundraise, its flagship private equity fund raises EUR 22 billion (USD 24 billion) in total commitments, of which EUR 21.7 (USD 23.5 billion) are fee-generating assets under management, exceeding the EUR 20 billion (USD 21.6 billion) target  · This represents a near 40 percent increase on EQT IX, thanks to strong support from existing and new investors, with a greater share of commitments coming from private wealth · EQT X builds on EQT Private Equity’s 30-year track record of strong performance, investing predominantly in the Healthcare, Technology and

GomSpace shows positive free cash flow during Q4 2023

In its Q4 2023 interim report, GomSpace shows strong evidence of the financial turnaround being on track with improved positive free cashflow of MSEK 21. Additionally, the company delivers a record high revenue for the full year of MSEK 235, and an order intake of MSEK 103, the highest since 2021.GomSpace Group AB (the “Company”) announces its interim report for the fourth quarter of 2023. Highlights Fourth quarter 2023 (2022) · Order intake was T.SEK 103,291 (27,880) · Net revenues decreased by 24% to T.SEK 38,403 (50,659) · Gross margin increased to 12% (negative 51%) ·

ZINZINO AB (PUBL): YEAR END REPORT 2023

AFTER STRONG RESULTS IN 2023, ZINZINO PROPOSES AN INCREASED DIVIDEND TO SEK 3 Revenues during the fourth quarter of 2023 amounted to SEK 527.9 (429.3) million, which corresponded to 23% (7%) growth compared to the corresponding period last year. The EBITDA result increased to SEK 71.3 (40.8) million and the EBITDA margin to 13.5% (9.5%). As before, behind the margin improvement are primarily changes in the sales mix, efficiencies and economies of scale. During the quarter, the company changed Certified Adviser to Carnegie Investment Bank AB and introduced a new customer loyalty program.

Invitation to the publication of Toivo Group Plc’s financial statement for 2023

Company release, 27 February 2024 at 9 a.m. Toivo Group Plc is organising an analyst and media event in conjunction with the publication of the financial statement for 2023 on Wednesday, 28 February 2024 at approximately 11:00. The financial statement will be presented as an audio webcast. The company announcement regarding the financial statement will be published on the same day at approximately 8:30. The financial statement will be presented by Toivo Group’s CEO Markus Myllymäki and CFO Samuli Niemelä. The event will be held in Finnish. Time: Wednesday, 28 February 2024 at

Systemair's Interim Report for the third quarter will be presented on March 5

PRESS RELEASE, 27 FEBRUARY 2024 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q3 for the financial year 2023/24 will be published at 07:00 CET on March 5, 2024. Press and analyst meeting will be organised at 09:00 CET on March 5, 2024. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO. To participate in the webcast: If you would like to participate in the webcast, please register via the link below.After registration, you will receive a link to confirm your email.There will be an opportunity to ask questions at any time during the

Stockmann’s report by the Board of Directors and Financial Statements 2023 have been published

STOCKMANN plc, Annual Financial Report 27.2.2024 at 9:00 EET   Stockmann’s report by the Board of Directors and Financial Statements 2023 have been published   Stockmann has published its Financial review 2023, which includes the report by the Board of Directors, the consolidated financial statements, parent company financial statements and the Auditor’s report. The disclosure of non-financial information is included in the report by the Board of Directors.   In addition, Stockmann has published its Corporate Governance report, Remuneration report, Business review and

Transaction in Own Shares

    27 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |26/02/2024|+----------------------------------------------------------

There are no items matching the current filter
There are no more items matching the current filter
Back to top